Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Quantum Genomics logo — Developing effective therapeutic treatments for controlling...

Quantum Genomics

Developing effective therapeutic treatments for controlling high blood pressure and preventing related cardiovascular risks such as heart failure

Founded 2006 France France 4 employees Biotechnology, Health Care

General Information

Company Name Quantum Genomics
Founded Year 2006
Location France France
Employees 4
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Quantum Genomics. To contact Quantum Genomics, visit quantum-genomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Quantum Genomics compare?

A PDF of Quantum Genomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Quantum Genomics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Quantum Genomics

Quantum Genomics is a French-based biotechnology company founded in 2006. The company is focused on developing effective therapeutic treatments for controlling high blood pressure and preventing related cardiovascular risks such as heart failure. Quantum Genomics aims to achieve this through the development of a new therapeutic class called BAPAIs (BrainAminopeptidase A Inhibitors). Their unique approach, based on the inhibition of brain Aminopeptidase A, represents a significant breakthrough in the field. High blood pressure remains a major public health concern, and Quantum Genomics is the sole biopharmaceutical research company working on new therapies derived from this innovation. Moreover, the company's mid-term strategic objective involves securing partnership agreements with major pharmaceutical companies to bring BAPAI technology-based products to the market. As Quantum Genomics operates in the Biotechnology and Health Care industries, it holds promising potential in addressing critical health issues. With no specific information available regarding the latest investment and investors, it remains to be seen how the company will secure funding for further growth and development. If successful, Quantum Genomics could play a significant role in transforming the treatment landscape for cardiovascular diseases.

Business keywords: biopharmaceutical research, cardiovascular diseases, therapeutic treatments, high blood pressure, Aminopeptidase A inhibitors, hypertension, heart failure, drug development, innovation, pharmaceutical partnerships

No funding data available for Quantum Genomics yet.

Quantum Genomics Alternatives & Competitors

View All Alternatives
Quantum Genomics vs
InterCure
InterCure

Harness the power of respiratory-based treatment for hypertension and heart failure with innovative...

Post-IPO Equity
Biotechnology, Health Care
Quantum Genomics vs
HEART METABOLICS LTD
HEART METABOLICS LTD Ireland

Heart Metabolics is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyop...

Series A
1 employees
Biotechnology, Health Care
Quantum Genomics vs
Gossamer Bio
Gossamer Bio United States

Vision * Connection * Innovation

Post-IPO Equity
159 employees
Biotechnology, Health Care
View all alternatives

FAQ About Quantum Genomics

Developing effective therapeutic treatments for controlling high blood pressure and preventing related cardiovascular risks such as heart failure
Quantum Genomics was founded in 2006.
Quantum Genomics is headquartered in France.
Quantum Genomics operates in Biotechnology and Health Care. Its work centres on biopharmaceutical research, cardiovascular diseases, therapeutic treatments and high blood pressure.
Quantum Genomics has approximately 4 employees.
Top alternatives and competitors to Quantum Genomics include InterCure, HEART METABOLICS LTD, Gossamer Bio, MEDIBIOFARMA SL, Cardurion Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Quantum Genomics and InterCure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Quantum Genomics, https://bouncewatch.com/company/quantum-genomics, updated 25 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout